Overview

Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis

Status:
Withdrawn

Trial end date:
2020-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to assess the early efficacy of treatment with BG00012 (dimethyl fumarate) 240 mg twice daily (BID) in the brain of newly diagnosed and naive-to-treatment patients with relapsing-remitting multiple sclerosis (RRMS). The Secondary objectives are to establish the time course of the beneficial effect of BG00012 240 mg BID over 24 weeks and to evaluate the safety of BG00012.

Phase:

Phase 4

Details

Lead Sponsor:

Biogen

Collaborator:

GB Pharma Services & Consulting S.r.l. Unipersonale

Treatments:

Dimethyl Fumarate